Álcool polivinil (PVA) para sistemas de entrega de drogas

Polyvinyl alcohol (PVA) for pharmaceutical drug delivery systems is a synthetic, water-soluble polymer obtained by controlled alcoholysis of polyvinyl acetate, yielding linear chains rich in 1,3-glycol units. Commercial product models are designated by a two-number code that encodes nominal solution viscosity at 20°C (first digit(s), 4% aqueous solution, in mPa·s) and degree of hydrolysis (second number, molar percentage of acetate groups removed). A model labeled 4-88, for example, corresponds to a grade with a viscosity of approximately 4.0–5.0 mPa·s and a hydrolysis level of 86–89 %. These molecular descriptors—weight-average molecular weights spanning 13 000 to 186 000 Da and residual acetyl content between 1 % and 30 %—determine critical performance attributes: aqueous dissolution temperature, film flexibility, crystallinity index, and drug-release kinetics. Monographs in USP-NF (current edition) and Ph. Eur. 10.0 (01/2023:1225) set identity, viscosity, acid value, loss on drying, and residue on ignition limits. The FDA’s Inactive Ingredient Database lists PVA for oral, ophthalmic, and topical routes with a maximum daily exposure of 15.4 mg for oral solids. Unlike biodegradable polyesters such as PLGA, PVA undergoes negligible enzyme-mediated chain scission in mammalian tissue, restricting its in vivo fate to dissolution, swelling, or permanent hydrogel formation rather than bioresorption.

What Governs the Selection Between Partially and Fully Hydrolyzed PVA Grades?

Partially hydrolyzed grades (86–89 %; e.g., PVA 18-88) dissolve in water at 25 °C because the random distribution of residual acetate groups disrupts inter‑chain hydrogen bonding sufficiently to lower crystalline melting below ambient temperature. Fully hydrolyzed grades (98–99 %; e.g., PVA 5-98) require heating above 85 °C for complete solvation and are thereby excluded from formulations containing thermolabile active pharmaceutical ingredients. The dissolution pattern directly modifies drug release from monolithic matrices: partially hydrolyzed PVA compacts, when tested in USP Apparatus 2 (paddle, 50 rpm, 900 mL pH 6.8 phosphate buffer), erode from the surface with a time‑dependent gel layer thickness that obeys a t^0.45 dependence, whereas the highly crystalline fully hydrolyzed matrix restricts water penetration to ≤ 12 % w/w after 2 h and extends zero‑order release over 8–12 h provided a channeling agent (e.g., 10 wt% lactose) is incorporated. Residual acetyl content also governs compatibility with plasticizers: at 20 % (w/w) glycerol, the glass transition temperature of a 88 % hydrolyzed film drops from 85 °C to 29 °C (DMA, 3 °C/min), meeting the ASTM D882‑18 flexibility threshold for blister‑pack coating; the same plasticizer load in a 99 % hydrolyzed grade fails to suppress T_g below 45 °C, producing a brittle film with elongation at break < 5 %.

Commercially available PVA for pharmaceutical use is supplied as a white to off‑white free‑flowing powder, with bulk density typically 0.4–0.6 g/cm³ and tapped density 0.6–0.8 g/cm³. Supplier certificates of analysis report viscosity measured on 4 % (w/w) aqueous solutions with a Brookfield LV viscometer at 20 °C and 60 rpm, conforming to the harmonized monograph. The table below collates the most common model designations and their pharmacopoeial-aligned specifications.

When Hot Melt Extrusion Replaces Aqueous Coating for Sustained‑Release Matrices

Formulating PVA by hot melt extrusion (HME) shifts the polymer from a simple coating agent to a thermoplastic matrix former, but the processing window is sharply confined by the proximity of the substance's crystalline melting region to its thermal degradation onset. Differential scanning calorimetry at 10 °C/min under nitrogen places the melting peak of fully hydrolyzed PVA at 228 °C, while acetic acid evolution—marking chain scission—begins as low as 200 °C in the presence of shear. Only partially hydrolyzed grades plasticized with low‑molecular‑weight polyols are realistically extrudable. On a co‑rotating twin‑screw extruder (Thermo Scientific Pharma 16, L/D 40, screw diameter 16 mm) fitted with a strand die of 2 mm, a formulation of PVA 4‑88 loaded with 20 wt% glycerol and 5 wt% microcrystalline cellulose as a processing aid was processed at barrel zone settings 130/145/160/170/175 °C (feed‑to‑die) and a screw speed of 150 rpm. Under these conditions steady‑state die pressure measured by a Terwin melt transducer was 18–22 bar, torque remained below 60 % of the motor rating, and the specific mechanical energy input was 0.14 kWh/kg. Reducing glycerol to 12 wt% without altering the thermal profile increased die pressure to 45 bar and caused severe shark‑skin surface defects on the extrudate, correlated with a zero‑shear viscosity η₀ exceeding 1.2 × 10³ Pa·s as measured by parallel‑plate oscillatory rheometry at 175 °C and 1 % strain. Thus, to maintain a stable extrusion front, η₀ must be held below 10³ Pa·s. This constraint contrasts with the behavior of hydroxypropyl methylcellulose (HPMC E5), which can be extruded without a plasticizer at barrel temperatures up to 210 °C while tolerating a melt viscosity of 2 × 10³ Pa·s without melt fracture.

Moisture management is critical: powder supplied with a loss‑on‑drying value above 0.8 % generates steam bubbles during extrusion and must be pre‑dried in a vacuum oven at 60 °C to ≤0.3 % residual moisture. Additionally, the presence of free aldehydes (e.g., from drug impurities or flavoring agents) initiates premature acetal crosslinking that elevates melt viscosity uncontrollably; formulations containing vanillin or cinnamaldehyde must be avoided. PVA also precipitates in the presence of high‑ionic‑strength salts such as sodium sulfate at concentrations above 6 % w/v, limiting its use in electrolyte‑rich matrix environments.

In head‑to‑head dissolution studies performed in USP Apparatus 2 at 50 rpm in pH 6.8 phosphate buffer (900 mL, 37 ± 0.5 °C), directly compressed PVA 18‑88 tablets containing 30 wt% diclofenac sodium released > 80 % of the payload within 6 h, driven primarily by swelling‑controlled diffusion. The same tablet geometry prepared with HPMC K100M required 12 h to reach equivalent release because the cellulose ether develops a thicker, more tortuous gel barrier. Conversely, PLGA (50:50, Mw 40 000) microparticles degrade by bulk hydrolysis of ester linkages, producing a tri‑phasic release profile with an initial burst, a lag phase, and a final erosion‑dominated stage, a mechanism unavailable to non‑biodegradable PVA. The table below summarizes key differentiation parameters relevant to formulation design.

Crosslinking Reactions and Gel Integrity in Physiological Fluids

Chemical crosslinking of PVA with glutaraldehyde (in the presence of catalytic HCl, 0.05 M), or with sodium borate at pH 8–9, creates three‑dimensional hydrogel networks whose equilibrium water content can be tuned from 70 % to 95 % w/w. After repeated freeze‑thaw cycles (−20 °C/25 °C for 8 cycles), physically crosslinked cryogels develop a storage modulus G′ of 15–40 kPa (oscillatory frequency sweep at 1 Hz, 37 °C) and resist dissolution even under simulated intestinal fluid containing pancreatin (USP SIF, pH 6.8). However, these gels lose approximately 20 % of their initial G′ when exposed to phosphate‑buffered saline at pH 7.4 for 28 days due to gradual disruption of crystalline junction zones, a limitation not observed in covalently crosslinked networks. Injectability through 21‑gauge needles requires a complex viscosity below 200 Pa·s at a shear rate of 100 s⁻¹; PVA solutions above 10 wt% typically exceed this threshold unless the molecular weight is reduced below 30 000 Da. All formulations intended for implantable use must meet the cytotoxicity criteria of ISO 10993‑5:2009, even if the polymer itself is considered intrinsically non‑toxic.